Patrys Ltd has released a press release.
PAT-DX3 proof of concept as potential ADC targeting antibody
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Patrys
- Appendix 4E and 2021 Annual Report
- Market Update - PAT-DX1 Clinical Trial Preparation
- Appendix 4C - Quarterly - 30 June 2021
- PAT-DX1 Improves Survival in Model of Pancreatic Cancer
- Full size deoxymab PAT-DX3 crosses the blood brain barrier
Later from Patrys
- Patrys proof of concept ADC significantly increases survival
- Appendix 4C - Quarterly - 30 September 2021
- $7.8M Capital Raising
- Rights Issue Offer Document
- Notification regarding unquoted securities - PAB
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys